20 51 the use of genome sequencing is expanding [Byrjalsen et al 2018]. Meanwhile, outside of the healthcare system, direct to 52 consumer (DTC) genetics expands rapidly providing the public with access individual genetic data profiles and to interpretation of 53 common genetic variants derived from genotyping microarrays. This is developing as a sprawling industry of consumer services 54 with widely diverging standards, including third-party genome analysis services. These services typically provide individual results 55 from analysis of single, common SNPs with (at best) weak effects. They are therefore severely mis-aligned with current state-of-56 the-art, which at least for common, complex disease is to use polygenic risk scores (PRS) to estimate the combined risk of 57 common variation in the genome [Lewis et al 2017].
To date, interpretation of genomic information has focused on single variants conferring disease risk, 21 but most disorders of major public concern have a polygenic architecture. Polygenic risk scores 22
(PRS) give a single measure of disease liability by summarising disease risk across hundreds of 23 thousands of genetic variants. They can be calculated in any genome-wide genotype data-source, 24 using a prediction model based on genome-wide summary statistics from external studies. 25
As genome-wide association studies increase in power, the predictive ability for disease risk will also 26 increase. While PRS are unlikely ever to be fully diagnostic, they may give valuable medical 27 information for risk stratification, prognosis, or treatment response prediction. 28
Public engagement is therefore becoming important on the potential use and acceptability of PRS. 29 However, the current public perception of genetics is that it provides 'Yes/No' answers about the 30 presence/absence of a condition, or the potential for developing a condition, which in not the case for 31 common, complex disorders with of polygenic architecture. 32
Meanwhile, unregulated third-party applications are being developed to satisfy consumer demand for 33 information on the impact of lower risk variants on common diseases that are highly polygenic. Often 34 applications report results from single SNPs and disregard effect size, which is highly inappropriate 35
for common, complex disorders where everybody carries risk variants. 36
Tools are therefore needed to communicate our understanding of genetic predisposition as a 37 continuous trait, where a genetic liability confers risk for disease. Impute.me is one such a tool, 38 whose focus is on education and information on common, complex disorders with polygenetic 39 architecture. Its research-focused open-source website allows users to upload consumer genetics data 40 to obtain PRS, with results reported on a population-level normal distribution. Diseases can only be 41 browsed by ICD10-chapter-location or alphabetically, thus prompting the user to consider genetic 42 risk scores in a medical context of relevance to the individual. 43
Here we present an overview of the implementation of the impute.me site, along with analysis of 44 typical usage-patterns, which may advance public perception of genomic risk and precision medicine. 45 46 3 1 Introduction 48 49
In clinical genetics, testing for rare strong-effect causal variants is routinely performed in the healthcare system to 50 confirm a diagnosis, or to evaluate individual risk suspected from anamnestic information [Baig et al 2016] , and in such instances equal, a design choice is that impute.me does not use risk-sorted lists. Currently scores are accessible either through an 112 alphabetically sorted list or in a tree-like setup where genetic scores are reported in a health-context-tree (figure 2B). In this, all 113 scores are included, but scores that are less relevant to healthy individuals (i.e. most of them), are buried deeper into the health-114 context-tree. As further discussed in the section Future Challenges, there are a lot of remaining challenges to solve on this 115 question.
117
3
Validation and testing 118
To evaluate pipelines on individuals with known disease outcomes, we investigated 242 samples from the CommonMind 119 data set. The CommonMind data set includes patients with schizophrenia, bipolar disorder and controls, from European ancestry 120 and from African ancestry. For each disorder and each ancestry group the full impute.me pipelines were applied, including 121 imputation and PRS-calculation. Additionally, SNP-sets corresponding to each of three major DTC companies were extracted and 122 re-calculated. This was done to test the hypothesis that PRS calculation in mixed SNP-sets poses particular challenges with 123 regards to missing SNPs. Such sets of genotyped SNPs that are different in each sample, is an unavoidable consequence of 124 working with online data uploads.
125
We found that disease prediction strength, measured as variability explained, corresponded well to theoretical 126 expectations of known SNP heritability [Li et al 2017 , Wünnemann et al 2019 . Secondly, we found that using all-SNP scores 127 resulted in better prediction than top-SNP scores, which was as expected [Vilhjálmsson et al 2015] . Thirdly, we found that 128 prediction was more accurate in individuals of European ancestry compared with individuals of African ancestry, which is This is a provisional file, not the final typeset article
To compare these findings with approaches that look at one SNP at the time, we extracted the SNPedia/Promethease 144 SNPs that were indicated as associated with schizophrenia [Cariaso et al 2011] . All cases (n=25) and all controls (n=39) had at 145 least one risk-variant from at least one of the 139 SNPs indicated schizophrenia associated. When focusing on SNPs that had 146 the SNPedia/Promethease-defined "magnitude"-level (sic.) at > 1.5, we found that 80% of the SCZ cases (20 of 25) had at least 147 one SNPedia/Promethease risk variant. Among the healthy controls 84% (33 of 39) had at least one such risk variant (p=0.9 for 148 difference in proportions). In other words, it is not very predictive to know if you have a schizophrenia SNP. This illustrates the 149 importance of considering more than one SNP at the time.
150
Finally, we compared pipeline reproducibility using two genome-data files, one obtained from MyHeritage and one from 151 Ancestry.com, but sampled from the same person. After processing through the impute-me pipelines the correlation between PRS 152 values over 1468 traits was r=0.933 between the two samples. Traits that showed discrepancy between the two data files typically 153 were based on only few SNPs, of which one did not meet imputation quality thresholds for one of the data files.
154 155 4
Evaluation of Usage 156
As of June 2019, a total of 28 651 genomes had been uploaded to impute.me, and a total of 3.1 million analytical 157 queries had been performed ( figure 4A ). The following additional observations about user behaviour may be of use to the genetics 158 research community.
159
Common and well-known diseases are the most sought after. By overall click-count and comparing over several 160 different modules, there is no doubt that users are most interested in common disease types; diseases of the brain, the heart and 161 of the metabolism are more requested. Interface design may of course play important roles in such choices. For example, the 162 choice to serve disease traits as alphabetically sorted lists is likely to artificially inflate interest in e.g. abdominal aneurysm (figure 163 4B). However, the larger interest in psychiatry, cardiovascular and metabolic disorders remain also in the precision medicine 164 module which is not presented as an alphabetically sorted list ( figure 4C ). It is possible that greater scientific interest in PRS in 165 these fields also drives some of these effects, but we cannot explain why other fields where PRS are actively discussed, such as 166 cancer, are not attracting more attention 167 Likewise, it seems that common disease ("Complex disease module") is more sought after than rare disease ("Rare 168 disease module"); 95% of all users visit the first, whereas only 70% visit the second. Again, interface design and project goals 169 probably play a big role in thisthe landing page headers says Beyond one SNP at the time and the rare disease module is Finally, we have observed that usage of health genetic data surprisingly often is not just a test-and-forget-event. When 174 plotting query-count as a function of time from first data-access, we find an expected pattern of intense browsing the hours and 175 days after first data access ( Figure 4D ). However, many users re-visit their data even months and years after first data access, 176 perhaps implying that results are considered and saved and then re-visited at a later time in a different context. 177 178 5
Future Directions 179
Generation of the PRS data presents one set of challenges but communicating them to people in such a way as to make it both 180 comprehensible and useful presents another [Lipkus et al 1999 , Naik et al 2012 . We believe that this is a crucial unmet need in 181 current genetics research, because presenting PRS data in a way that is useful requires an understanding of people's motivations 182 for accessing them in the first place.
183
To date, studies of PRS have focused on providing people with PRS information in relation to specific conditions (e.g. cancer figure 1C ). Currently we have registered the SNP-heritability for 294 of the reported traits, available as an experimental option 199 called 'plot heritability'. We believe that a main future direction is to experiment and expand on how to best communicate this to Conclusion 209
In summary, impute.me is a fully operational genetic analysis engine covering a very broad range of health-related traits, 210 specifically focusing on optimizing possibilities from microarray-based DNA measurements. The challenges, their solutions, and 211 the curation work behind them are highly relevant today in a setting of highly varying quality in interpretation of personal consumer 212 genetics. They will also continue to be relevant in a future where we can expect both increases in the predictiveness of polygenic 213 risk scores, as well as vast increases in the number of individuals buying consumer genetics. With a directed push towards 214 responsible use of consumer genetics, this may even prove to be an overall clinical benefit. From the pre-processed data a modular set of trait predictor algorithms are applied. For many of the 244 modules, the calculations are trivial. For example, this could be the reporting of presence and/or 245 absence of a specific genotype, such as ACTN3 and ACE-gene SNPs known to be (weakly) 246 associated with athletic performance. These are included mostly because users expect them to be. For 247 other, we rely heavily on PRS. 248 An important distinguishing factor between different PRS algorithms is how risk alleles are selected. 249
A commonly used approach includes variants based on whether they surpass a given p-value 250 threshold in the GWAS, retaining only LD-independent variants using LD-based clumping, often 251 with a p-value threshold of genome-wide significance (p<5e-8). Herein we refer to this approach as 252 the 'top-SNP' approach. The top-SNP approach has the advantage that it is simple to explain, is easy 253 to obtain for many GWAS, and has a light computational burden, e.g. In the top-SNP calculation mode, the results are scaled such that the mean of a population is zero and 263 the standard deviation (SD) is 1, according to the relevant 1000 Genomes super-population; either 264
African, Ad Mixed American, East Asian, European or South Asian.
Zero-centered-score = Σ Betasnp * Effect-allele-countsnp -Population-scoresnp 267 Z-score = Zero-centered-score / Standard-deviationpopulation 268
Where beta (or log(odds ratio)) is the reported effect size for the SNP effect allele, frequencySNP is the 269 allele frequency for the effect allele, and the Effect-allele-countSNP is the allele count from genotype 270 data (0, 1, or 2). 271
In the all-SNP calculation, the scaling is similar, but done empirically, i.e. based on previous 272
Impute.me users of matching ethnicity. This mode of scaling is also available as an optional 273 functionality in the top-SNP calculations, and generally seems to match well with the default 1000 274 genomes super population scaling. 275
The all-SNP scores were derived using weightings from the LDpred algorithm [Vilhjálmsson et al 276 2015] . This algorithm adjusts the effect of each SNP allele for those of other SNP alleles in linkage 277 disequilibrium (LD) with it, and also takes into account the likelihood of a given allele to have a true 278 effect according to a user-defined parameter, which here was taken as wt1 i.e. the full set of SNPs. 279
The algorithm was directed to use hapmap3 SNPs that had a minor allele frequency >0.05, Hardy-280
Weinberg equilibrium P>1e-05 and genotype-yield >0.95, consistent with our expectation that these 281 would be the best imputed SNPs after full pipeline processing. 282
Pipeline Testing 283
The CommonMind genotypes measured with the microarray of the type H1M were downloaded 284 along with phenotypic information. Each sample was processed through the impute.me pipelines, 285 using the batch-upload functionality. Reported ethnicity was compared with pipeline (genotype) 286 assigned ethnicity and found to be concordant. This is a provisional file, not the final typeset article After pipeline completion, we extracted three PRS for each sample, corresponding to SCZ all-SNP, 288 SCZ top-SNP and BP all-SNP. In the github-repository for impute.me, these three corresponds to the 289 scores labelled SCZ_2014_PGC_EXCL_DK. EurUnrel.hapmap3.all.ldpred.effects, 290 schizophrenia_25056061, BIP_2016_PGC.All.hapmap3.all.ldpred.effects trait-IDs [PGC 2014 , Hou 291 et al 2016 . These extracted scores formed the basis of the row #1 and #4 calculations in figure 3 . The 292 remaining rows were created by subsetting the best guess imputed genotypes into new sets of users, 293 corresponding to each of three major DTC vendors and then re-running the scoring algorithms either 294 with uniform data or mixed data. Uniform data is here defined as all samples 195 samples having the 295 same set of SNPs available, corresponding to one of three DTC vendors in each run. Mixed data is 296 defined as samples having different sets of SNPs available, a set corresponding to actual distributions 297 of customers from different DTC vendors, with distributions re-drawn 100 times. We estimated the 298 predictive ability of the PRS using Nagelkerke's R 2 and AUC. 299
Usage evaluation 300
A log data freeze was performed 2019-06-08, by making a copy of all usage log files and then 301 removing the uniqueID of each user. This was done to prevent it from being linked with the genetic 302 data of that user. The exception was the publicly available permanent test user with ID 303 id_613z86871, which was lifted out before analysis and is not included in other summary statistics. 304
Generally, a user corresponds to an uploaded genome with a unique md5sum. Click-through rates 305 were calculated as fraction of users that performed any query in the module in question, e.g. the 306 precision medicine module was only launched in September 2018 and therefore only counts clicks 307 from people who have used it. Plots were generated using base-R version 3.4.2 and cytoscape version 
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This is a provisional file, not the final typeset article 322 Fig.2 Theoretical background of the analysis pipeline A) Clinical genetics currently concern high-effect DNA-variants that 323 often can only be sequenced (red). Additionally, high-effect variants such as APOE4 and a small subset of BRCA1 and BRCA2 324 pathogenic variants are possible to measure using microarray (blue, includes several other variants not shown in plot, e.g.
325
Parkinson's variants). There may be an untapped potential for valuable clinical information in polygenic risk scores (PRS) for This is a provisional file, not the final typeset article each disease-entry is presented on an alphabetically sorted list, with aortic aneurysm being the default value. The percentage 360 indicates how many of the users that scrolled down and selected this disease at least once (nclicks = 871855). C) Distribution of 361 interests in a trait in the precision medicine module. In this module, each disease-entry is presented in the layout of the ICD-10 362 classification system. The click through-rate reflects how many users pursued information in a given chapter or sub-chapter, as The manuscript describes an approach for obtaining polygenic risk scores (PRS) for any individual 392
using direct-to-consumer genetics. PRS are considered state-of-the-art for genetic prediction in common, complex diseases, and the availability of such methods therefore have the potential expand 394 the usage of genetics beyond rare mendelian disorders. At the same time, the usage and interpretation 395 of direct-to-consumer genetics is by many considered a controversial issue that needs more 396 regulatory oversight. 
